Clinical Trial Update: QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating QL1706 in combination with Bevacizumab and RALOX-HAIC for hepatocellular carcinoma with portal vein tumor thrombosis is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Portal Vein Tumor Thrombosis

Drugs mentioned

• Bevacizumab (bevacizumab)
• OXALIPLATIN (Oxaliplatin)
• QL1706
• Raltitrexed (Raltitrexed)

Snippet

Sponsor: Nanfang Hospital, Southern Medical University | Conditions: Hepatecellular Carcinoma, RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin | Phase 2 | Status: RECRUITING